Journal Articles (the latest 5 yrs)

• M Yu, L Ai, B Wang and et al. GenomePAM directs PAM characterization and engineering of CRISPR-Cas nucleases using mammalian genome repeats. Nature Biomedical Engineering, 2025, 10(2):231–244. [Cover story]
• B Fang, P Qiu, C Xia and et al. Extracellular matrix scaffold crosslinked with vancomycin for multifunctional antibacterial bone infection therapy. Biomaterials, 2021, 268:120603. [Co-corresponding]
• B Wang, X Lv, Y Wang and et al. CRISPR/Cas9-mediated mutagenesis at microhomologous regions of human mitochondrial genome. Science China-Life Sciences, 2021, 64(9):1463-1472.

Conference Works (the latest 5 yrs)

• B Wang, Y Cao, Z Jiang and et al. Safe and Efficient Editing of Novel CRISPR-Cas Ribonucleoprotein Complexes Delivered by Engineered Protein Delivery Vehicle. American Society of Gene and Cell Therapy, 2025, New Orleans, LA. [Oral talk]
• B Wang, Y Cao, M Yu and et al. A Catalogue of Novel Type II CRISPR Nucleases with Diverse PAM Preferences. American Society of Gene and Cell Therapy, 2024, Baltimore, MD.
• B Wang, N WY Wong, M Yu and et al. Development of De Novo Mining Platform for Discovery and Identification of Novel Small Class II CRISPR Nucleases with Expanded PAM Preference. American Society of Gene and Cell Therapy, 2023, Los Angeles, CA.
• Q Xia, B Wang, Z Zhou and et al. High-Throughput Screening Platform of Lipid Nanoparticles for In Vivo CRISPR/Cas Gene Editing. American Society of Gene and Cell Therapy, 2023, Los Angeles, CA.
• B Wang, M Yu, Z Zheng. Sensitive One-step Discovery and Validation of CRISPR Off-targets Using EDITED-Seq. Cold Spring Harbor Laboratory Conference, 2022, New York, NY.

Preprints